3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Lymphoid
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Advanced Solid Tumors
4
Squamous Cell Carcinoma of Head and Neck
3
Carcinoma, Renal Cell
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Melanoma
2
Esophageal Neoplasms
2
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Solid Tumor, Unspecified, Adult
1
Solid Tumor
1
Pharyngeal Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Multiple Myeloma
1
Mouth Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Head and Neck Neoplasms
1
Erythrocytosis, Familial, 4
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Interventions
Cyclophosphamide
58
Rituximab
54
fludarabine
33
fludarabine phosphate
32
venetoclax
24
Filgrastim
22
Etoposide
18
Bendamustine Hydrochloride
18
Gemcitabine
17
Peripheral Blood Stem Cell Transplantation
15
Bortezomib
15
Melphalan
14
obinutuzumab
13
Lenalidomide
12
Dexamethasone
12
Cytarabine
12
Vincristine
11
Vorinostat
10
Tacrolimus
10
Azacitidine
10
pembrolizumab
9
Prednisone
9
Mycophenolic Acid
9
Doxorubicin
9
ibrutinib
8
copanlisib
8
Whole-Body Irradiation
8
Radiotherapy
8
Paclitaxel
8
Interleukin-2
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Lymphoma, Non-Hodgkin
×
zimberelimab
×
Clear all
NCT04772989
2025-08-28
ARC-12
Arcus Biosciences, Inc.
Phase 1
Completed
94 enrolled